Dva overwatch ( Akeno.cosplay)

DVA (Overwatch) by me

Dva Stadium Showdown Cosplay by gintkunya

Earth’s 27.5-Million-Year Pulse: The Planet’s Mysterious Rhythmic Upheaval
Scientists have uncovered something astonishing: Earth seems to operate on a hidden clock.
Every 27.5 million years, our planet goes through a powerful geological reset — a "heartbeat" that triggers mass extinctions, giant volcanic eruptions, tectonic shifts, and dramatic sea-level changes.

In a study published in Geoscience Frontiers, researchers analyzed 89 major geological events over the past 260 million years. The result? These catastrophic moments don’t happen randomly — they occur in predictable clusters, spaced out like rhythmic pulses in deep time.

What Happens During These Pulses?
Global mass extinctions (land and sea)
Supervolcanic eruptions (like continental flood basalts)
Oxygen-starved oceans (anoxic events)
Rising or falling sea levels tied to climate shifts
Massive tectonic reorganizations

This isn't a brand-new theory — as early as the 1920s, scientists suspected a 30-million-year cycle. But now, with more data and advanced analysis, 27.5 million years has emerged as the most consistent interval.

It’s a stunning idea: that Earth’s most violent transformations follow a deep, cosmic rhythm — a geological metronome shaping life, death, and rebirth across eons.

Source:
Rampino, M.R. et al. (2021). "A pulse of the Earth: A 27.5-Myr underlying cycle in coordinated geological events over the last 260 Myr." Geoscience Frontiers.

Researchers have developed a non-invasive urine-based diagnostic test that can accurately detect pancreatic and prostate cancers.

This advancement is particularly significant because both cancers are notoriously difficult to diagnose early, especially pancreatic cancer, which often presents symptoms only in advanced stages.

-- Scientific Basis:

The test works by identifying specific biomarkers—molecules or genetic materials (like RNA, proteins, or metabolites)—in urine samples.

These biomarkers are associated with early tumor growth and can indicate the presence of cancerous activity before traditional imaging or blood tests might detect anything.

For pancreatic cancer, urinary biomarkers such as LYVE1, REG1A, and TFF1 have shown strong diagnostic potential in peer-reviewed studies.

For prostate cancer, the test may analyze exosomal RNA (like PCA3 or TMPRSS2:ERG fusion transcripts), which are known to be secreted in urine by prostate cancer cells.

-- Accuracy:

Some recent clinical trials and pilot studies have demonstrated over 90% sensitivity and specificity for these urine tests, meaning they are quite accurate at distinguishing cancerous from non-cancerous conditions.

However, these findings still need broader validation before becoming standard practice in hospitals.

-- Development Sources:

Institutions like University College London (UCL), Johns Hopkins, and startups in the biotech sector have published promising results in journals such as Clinical Cancer Research and Nature Communications.

Ongoing research is backed by cancer foundations and NIH grants.

-- Impact:

This type of urine-based test is quick, painless, and affordable, making it ideal for early cancer screening and widespread public health initiatives.

It could drastically improve early detection rates and reduce mortality, especially in underserved populations where access to imaging and biopsies is limited.